FDA Investigator Dr. Jun Liu, PhD
Dr. Jun Liu, PhD has conducted inspections on 8 sites in 3 countries as of 30 Oct 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
30 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
China,
Japan,
United States of America
FDA Investigators that have inspected at least one site in common with Dr. Jun Liu, PhD:
Amanda L Fyles,
Bo Chi, PhD,
Bryan A Galvez,
Chen Sun, PhD,
Chikako Torigoe, PhD,
Christopher R Czajka,
Christopher T Middendorf,
Cynthia Jim, CSO,
Davinna Ligons, PhD,
Dennis Cantellops Paite,
Diane L Raccasi,
Dr. Ralph M Bernstein, PhD,
Emine Guvenmaiorov,
Frances Namuswe, PhD,
Gene D Arcy,
Ian L Mcwilliams,
Ivis L Negron,
Jacek Cieslak, PhD,
Jolanna A Norton,
Jonathan W Chapman,
Jorge L Guadalupe,
Kevin A Gonzalez,
Kristen Nickens, PhD,
Laurimer Kuilan Torres,
Lindsey Brown, PhD,
Lindsey S Fleischman,
Madushini Dharmasena, PhD,
Marion Michaelis,
Mekonnen Lemma Dechassa, PhD,
Michael Shanks, MS,
Ramesh Potla, PhD,
Ramon A Hernandez,
Scott R Nichols, PhD,
Scott T Ballard,
Steven E Bowen, PhD,
Thao T Kwan,
Thuy T Nguyen, LCDR,
Viviana Matta,
Wayne E Seifert,
Yi Wang, PhD,
Yiwei Li,
Yun Wu, PhD,
Zachary L Stamm,
Zhong Li, PhD
Dr. Jun Liu, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| January, 2023 | FDA 483 | Tanvex BioPharma USA, Inc - Form 483, 2023-01-24 |
| December, 2017 | FDA 483 | Kyowa Kirin Co., Ltd. - Form 483, 2017-12-21 |
| July, 2021 | FDA 483 | Daiichi Sankyo Chemical Pharma Co., Ltd.- Tatebayashi - Form 483, 2021-07-02 |
| November, 2019 | FDA 483 | Daiichi Sankyo Chemical Pharma Co., Ltd.- Tatebayashi - Form 483, 2019-11-01 |
| May, 2023 | FDA 483 | WuXi Biologics Co., Ltd. - Form 483, 2023-05-09 |
| November, 2019 | FDA 483 | Daiichi Sankyo Chemical Pharma Co., Ltd. - Form 483, 2019-11-08 |
| July, 2021 | FDA 483 | Daiichi Sankyo Chemical Pharma Co., Ltd. - Form 483, 2021-07-09 |
| November, 2023 | FDA 483 | FUJIFILM Diosynth Biotechnologies Texas, LLC - Form 483, 2023-11-07 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more